Skip to main content
Fig. 2 | Cancer Cell International

Fig. 2

From: Midazolam increases cisplatin-sensitivity in non-small cell lung cancer (NSCLC) via the miR-194-5p/HOOK3 axis

Fig. 2

Midazolam enhanced cisplatin’s cytotoxic effects on CR-NSCLC cells. The CR-NSCLC cells were respectively treated with cisplatin and midazolam for 0 h, 6 h, 12 h, 24 h and 48 h, and A, B MTT assay and C, D trypan blue staining assay were used to measure cell proliferation and viability. EG At 24 h post-treatment, cell apoptosis ratio was evaluated by using the FCM assay. The xenograft tumor-bearing mice models were established by using the A549/DDP cells, and H, I tumor weight and (J) volume were monitored to evaluate tumor growth in vivo. K, L The mice tumor tissues were collected and prepared, and the expression status of pro-proliferation Ki67 protein was determined by IHC, which were quantified by using the H-score. Individual experiment contained at least 3 repetitions, and *P < 0.05, **P < 0.01, and ***P < 0.001 was considered as statistical significance

Back to article page